iShares US Healthcare (IYH)
NYSEArca - NYSEArca Delayed Price. Currency in USD
- Market Realist•21 days ago
Pfizer’s (PFE) Xeljanz (or tofacitinib) is a first-in-class Janus kinase (JAK) inhibitor, and Xeljanz XR is its extended-release tablet form.
- Market Realist•24 days ago
Pfizer’s (PFE) Ibrance was first approved for advanced breast cancer in February 2015. In February 2016, it was further extended to treat recurrent breast cancer.
- Market Realist•25 days ago
Eli Lilly and Co. (LLY) reported growth of ~8.6% in revenues for 2Q16—compared to 2Q15. Its 2Q16 revenues surpassed Wall Street analysts’ estimates.